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Summary
Elevation of the mean pulmonary arterial pressure to ≥25
mm Hg within the low-pressure system of the pulmonary
circulation is defined as pulmonary hypertension. Pulmon-
ary hypertension may be the consequence of various clin-
ical and pathophysiological entities. Many of these condi-
tions, however, result in a final common pathway of patho-
genesis. This pathway is characterised by the triad of ex-
cessive vasoconstriction, microthrombosis and remodelling
of pulmonary arteries. Remodelling is arguably the most
important factor: its complex pathogenesis is not com-
pletely understood and no specific treatment directly tar-
gets vascular remodelling. This article aims to review the
current understanding of the pathogenesis of pulmonary
hypertension and to give insights in future developments in
this evolving field.
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Introduction
Pulmonary hypertension is an umbrella term [1] used for
many different conditions that are all defined by an in-
crease of the mean pulmonary arterial pressure (mPAP) to
25 mm Hg or more [2]. About 30 entities that result in
such pulmonary pressure elevation are recognised by the
World Health Organization classification of pulmonary hy-
Figure 1
The three pieces in the pathogenesis of pulmonary
hypertension. Pure vasoconstriction occurs in early disease;
microthrombotic events are observed at increasing frequency
during evolution of the disease; remodelling of the small pulmonary
arteries is arguably the most important factor.
pertension [3]. Based on clinical and pathophysiological
features, these entities are further divided into five groups.
Group 1, pulmonary arterial hypertension (PAH), includes
the idiopathic and hereditary forms in addition to disease
associated with predisposing conditions, such as infection
with human immunodeficiency virus, liver cirrhosis,
connective-tissue disease and congenital heart disease.
PAH induced by the use of drugs (e.g. anorexigenic agents)
is also included in this group. Group 2 is classified as pul-
monary hypertension due to left-sided heart disease; Group
3 includes hypoxia-induced elevations of the pulmonary
pressure and pulmonary hypertension associated with lung
disease; Group 4 includes those where chronic thromboem-
bolic events result in an increase of the pulmonary pres-
sure. Lastly, Group 5 is pulmonary hypertension due to
miscellaneous disorders that, pathophysiologically, cannot
be attributed to one distinct group (for example pulmonary
hypertension in the context of sarcoidosis or myeloprolif-
erative disorders).
Most studies in the field, independent of whether they were
designed for pharmaceutical interventions or to address ex-
perimental questions, have been conducted in PAH, which
is an orphan disease (the worldwide incidence rate of PAH
is difficult to estimate, registry data report incidence rates
of 1–7 cases per million [4, 5]). The development of PAH
and, moreover, both its aggravation and acceleration, is
thought to be mediated by the combination of genetic vari-
ants that predispose an individual to develop PAH, and a
second factor such as inflammatory activity and/or infec-
tion which than triggers the onset of active disease [6]. In-
terestingly, gender appears to play a key role in disease
risk, with premenopausal women having a two- to four-
fold higher risk of developing PAH than men. However,
upon disease diagnosis, females have a more favourable
prognosis than men and also show a better response to vas-
odilator therapy [7, 8]. In contrast to the predominance of
female patients in the clinic, experimental data from animal
models suggest that female animals are, at least in part, pro-
tected from the development of pulmonary hypertension by
the effects of oestrogen [9]. This phenomenon is referred to
as the “oestrogen paradox” or “sexual dimorphism” of pul-
monary arterial hypertension.
There are three major pathogenetic features of PAH – vaso-
constriction, microthrombotic events and vascular remod-
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elling of the small pulmonary arteries (fig. 1) – which are
not exclusive to this disease but are present in most forms
of pulmonary hypertension.
This article aims to discuss the current developments in our
understanding of the three major pathogenetic factors in
pulmonary hypertension.
Vasoconstriction
Vasoconstriction of pulmonary arteries is an essential
factor in the pathogenesis of pulmonary hypertension and,
when present without microthrombosis and vascular re-
modelling, probably represents an early and potentially re-
versible stage in the development of the disease. This is re-
flected by the fact that vasoresponders (i.e. patients who
show a substantial reduction of the mPAP of >10 mm Hg
below a value of 40 mm Hg upon inhalation of vasoactive
compounds) have an excellent prognosis when treated with
calcium channel blocking agents [10, 11]. Moreover, sev-
eral cardiopulmonary reflexes mediate pulmonary pressure
elevation by vasoconstriction upon distinct triggers such
as hypoxia (hypoxic pulmonary vasoconstriction or Euler-
Liljestrand reflex) and left atrial hypertension (Hermo-
Weiler or Kitaev reflex) (reviewed in [12]). Hypoxia also
decreases the expression of potassium channel proteins and
results in depolarisation of the membrane of pulmonary
artery smooth muscle cells. These mechanisms, in turn, in-
duce calcium influx and calcium release from intracellu-
lar stores, resulting in smooth muscle cell contraction [13].
The pathogenetic role of ion channels has been emphasised
by a recent study that identified mutations in KCNK3 (po-
tassium channel subfamily K, member 3) (“channelopath-
ies”) in patients with hereditary PAH [14].
Vasoconstriction is mainly mediated by an imbalance of
vasoactive factors, i.e. an excess of vasoconstrictors and
a concomitant deficiency of vasodilating mediators. Three
major pathways have been described for this, through the
action of prostacyclins, endothelin-1 and nitric monoxide
[15], all of which have been found to be dysregulated in
pulmonary hypertension. For example, 20 years ago, Gi-
aid and coworkers described decreased expression levels
of endothelial nitric oxide synthase in patients with PAH
compared with controls [16], which suggests a reduced
bioavailability of the potent vasodilator nitric oxide (NO)
and its second messenger cyclic guanine monophosphate
(cGMP). In addition, in patients with pulmonary hyperten-
sion with concurrent chronic haemolysis or sickle cell dis-
ease, it has been found that the release of arginase from
erythrocytes leads to degradation of arginine, which is an
important substrate for NO [17]. Current therapies address
the shortage of NO by decreased degradation of cGMP
through inhibition of phosphodiesterase-5 or, conversely,
by increased cGMP production through stimulation of the
soluble guanylate cyclase. Similarly, the levels of vasore-
active prostacyclins and their second messenger cAMP
(cyclic adenosine monophosphate) are reduced in patients
with PAH [18]. This, at least in part, might be explained by
a decreased expression of prostacylin synthase in lung tis-
sue of patients with PAH [19]. Endothelin-1 is one of the
most potent endogenous vasoconstrictors [20]. Increased
levels of endothelin-1 were detected in lung tissue of PAH
patients and circulating protein levels were found to be
higher than in controls [21]. Of note, these levels were
found to correlate with the severity of pulmonary pressure
elevation [22]. Endothelin-1 acts through endothelin-A and
-B receptors which are located on endothelial (ET1-B) and
vascular smooth muscle cells (ET1-A and -B). Vasocon-
striction is mainly mediated by ET1-A receptors whereas
ET1-B receptors have been described as neutralising circu-
lating Endothelin-1 [23]. However, the development of se-
lective antagonists against ET1-A receptors has not resul-
ted in better clinical results as compared with dual receptor
blockade.
The important role of all three pathways involved in vaso-
constriction is highlighted by the clinical success of PH-
targeted therapies [24]. However, it is important to note
that while these therapies have been shown to improve dra-
matically symptoms and quality of life of PAH patients,
none of them cure the disease.
Thrombosis
Microthrombotic events play an important role in the evol-
ution of PAH. Such events are observed at increasing fre-
quency in older patients with longstanding disease. Several
coagulopathies have been described in patients with PAH,
including protein C and S deficiency (resulting in reduced
endogenous anticoagulation) and increased von Willebrand
factor activity (resulting in increased procoagulatory activ-
ity) [25, 26]. However, since many coagulation factors are
acute-phase proteins and inflammation is an emerging
concept in the pathogenesis of pulmonary hypertension
[27], it remains unclear whether the observed alterations in
the expression of coagulation factors are of true pathogen-
etic relevance. Experimental studies in animal models of
the disease have recently suggested an active role for the
coagulation factor Xa (FXa) [28]. As such, direct inhibi-
tion of FXa by the application of rivaroxaban was more ef-
fective in preventing right ventricular hypertrophy as com-
pared with warfarin or placebo. However, no data exist on
the use of novel oral anticoagulants in PAH patients. The
only prospective study to date conducted to elucidate the
role of oral anticoagulation has found a survival benefit
in patients with idiopathic PAH when treated with cou-
marins. In all other forms of PAH the results were incon-
clusive [29]. For the prevention of microthrombotic events,
we think that in the absence of clear contraindications, the
use of oral anticoagulation is supported by the importance
of this pathogenetic concept not exclusively in idiopathic
forms but also in other patients with PAH.
Remodelling
Remodelling is a key factor in the pathogenesis of PAH
and, during recent years, has been associated with a
neoplastic-like process. Such a notion is supported by sev-
eral mechanisms involved in vascular remodelling, such as
uncontrolled proliferation, altered metabolism, clonal ex-
pansion, somatic instability and resistance to programmed
cell death [30]. Remodelling might involve both arterial
and venous components of the pulmonary vascular bed: In
small pulmonary arteries (<300 um), remodelling is char-
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acterised by excessive proliferation of cells in all vascular
layers (fig. 2), in particular by uncontrolled proproliferative
Figure 2
Features of pulmonary artery vascular remodelling in different
cell types. All vascular cell types (endothelial cells, smooth muscle
cells and adventitial fibroblasts) are involved in pulmonary artery
remodelling and are characterised by excessive proliferation. The
accumulation of myofibroblasts and extracellular matrix proteins
within the endothelial layer is termed “neointima”. Plexiform lesions
(shown by white star) are a system of thin-walled, dilated vessels
as consequence of endothelial proliferation. These lesions are
found exclusively in pulmonary arterial hypertension (PAH). The
most prominent changes are observed within the vessel’s medial
layer and mediated by a imbalance between proproliferative and
apoptotic activity of smooth muscle cells and transmigration of
these cells and myofibroblasts in the endothelial layer. Within the
adventitial layer, neovascularisation of vasa vasorum and increased
production of matrix proteins is observed (shown by Elastin-Van
Gieson (EVG) staining). These alterations result in excessive
hyperplasia, increased vessel thickness and luminal occlusion
(reviewed in [70]).
Figure 3
Overview of important factors in pulmonary vascular
remodelling. BMPR2 is expressed on pulmonary artery smooth
muscle cells and is the master regulator in remodelling of
pulmonary arteries. Upon binding of ligands, BMPR2 and BMPR1
dimerise and activate proapoptotic genes through the action of the
transcription factors Smad and Id (inhibitor of differentiation).
Dysregulation of this pathway, for example due to mutations in
BMPR2, results in a proproliferative state. Inflammatory cytokines
(e.g. interleukin-6 [IL-6]) phosphorylate the transcription factor
STAT3 and induce the expression of miRNAs. MicroRNAs act as
gene silencers and downregulate BMPR2, which directly inhibits
cell cycle regulators. Ion channels, serotonin transporters and
receptors associated with tyrosine kinase signalling are also
involved in mediating vasoconstriction and remodelling.
activity of smooth muscle cells. Remodelling of venules
is less well defined, but may be prominently observed in
pulmonary venoocclusive disease and in postcapillary pres-
sure elevation due to left-sided heart disease [31].
Anecdotal reports have described substantial improvement
of PAH patients when treated with tyrosine kinase inhib-
itors (in particular with imatinib) resulting in “cure”, or
weaning of intravenous vasoactive therapy [32, 33]. A
small recent study has confirmed these findings and sug-
gested improvement of functional class and quality of life
in patients treated with imatinib [34]. Improvement under
this therapy is attributed to antiproliferative activity and
“reverse remodelling”. However, no pathological examin-
ation has confirmed such effects and, moreover, tyrosine
kinase inhibitor therapy is limited by lack of specificity
and substantial adverse effects [35, 36]. To date, no PH-
targeted therapy addresses vascular remodelling, which re-
mains the Achilles heel in the long-term treatment of PAH
patients and, still, defines chronicity, progression and in-
curability of the disease.
The pathogenesis of remodelling is not completely under-
stood and is mediated by a plethora of growth factors, mito-
gens, cytokines, ion channels, receptors, neurotransmitters,
viruses and transcription factors [37, 38]. This is shown in
simplified form in figure 3. One of the hallmark factors
within this complex network is the bone morphogenetic
protein receptor type II (BMPR2), a member of the trans-
forming growth factor-beta superfamily. BMPR2 is argu-
ably the most investigated and, so far, the most important
regulator of vascular remodelling of pulmonary arteries.
BMPR2 is expressed on pulmonary endothelial and vascu-
lar smooth muscle cells. Upon binding of specific ligands
(in particular BMP-2 and also BMP-4), BMPR2 heterodi-
merises with BMPR1 resulting in activation of Smad and
Id (inhibitor of differentiation) proteins. These downstream
signalling events activate master regulators of cell cycle
control (e.g. p21 or CDKN1A) and, in turn, inhibit pro-
liferation, activate apoptosis and induce cell senescence.
In 70% of patients with hereditary PAH and in as much
as 20% of patients with idiopathic PAH, loss-of-function
mutations in the BMPR2 gene have been identified [39,
40] and many of these are gene rearrangement or de-novo
mutations [41, 42]. Moreover, nongenetic dysregulations of
BMPR2 are observed in many secondary forms of PAH
– including hypoxia-induced pulmonary hypertension [43,
44], pulmonary hypertension associated with systemic
sclerosis [45], chronic heart failure [46], congenital heart
disease [46, 47] and human immunodeficiency virus infec-
tion [48]. In all of these diseases, the protein expression of
BMPR2 is reduced. Of interest, regulation of BMPR2 sig-
nalling is also controlled by endothelin-1 [49], which might
provide an interesting link between vasoconstriction and
remodelling. Evidence suggests that dysfunctional BMPR2
results in the imbalance of proliferation and apoptosis,
which, in turn, leads to vascular remodelling.
Mutations in BMPR2 were first identified in PAH patients
15 years ago and, to date, more than 20 disease-relevant
mutations have been identified [40]. Hereditary PAH also
includes mutations in other disease-relevant genes, for ex-
ample mutations in the activin receptor-like kinase-1
(ALK-1) [50] or, as mentioned above, in the gene coding
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for the potassium channel KCNK3 [14] (reviewed in [31]).
However, mutations within the BMPR2 gene are the most
common and dysregulations of BMPR2 resulting in func-
tional defects make BMPR2 to an interesting pathogenetic
and therapeutic target beyond identifiable genetic aetiolo-
gies of the disease. The reason for the downregulation of
BMPR2 in nongenetic entities is not clear. We and others
have provided a mechanistic explanation for the dysreg-
ulation of BMPR2 and, by the identification of specific
microRNAs, set off the “era of noncoding RNAs in pul-
monary hypertension” [51, 52]. Noncoding RNAs include
housekeeping RNAs (for example, ribosomal RNA and
transfer RNA), small noncoding RNAs (with a length of
fewer than 200 nucleotides), and long noncoding RNAs
(>200 nucleotides) [53]. Since these RNA fragments have
no encoding function they have long been discarded as ge-
netic “junk” [54]. Within the last few years, however, non-
coding RNAs have emerged as important gene silencers in
many diseases including respiratory disorders [55, 56], and
it is estimated that more than 60% of the human genome is
under the regulatory control of these noncoding RNAs – of
which microRNAs (miRNAs) are the most investigated to
date [57].
MicroRNAs are composed of 18–22 nucleotides and, fol-
lowing a complex biogenesis, bind as single stranded RNA
through Watson-Crick base pairing to the mRNA sequence
of a target gene. This binding process triggers either the
truncation of the targeted mRNA or the translation of
mRNA into protein without affecting mRNA stability. As
such, miRNAs act as post-transcriptional gene silencers. In
the aftermath of the initial description of miRNAs with pul-
monary hypertension [58], a plethora of papers has been
published on this topic. In our opinion, the most important
miRNAs involved in PAH pathogenesis are those derived
from the cluster miR-17-92, which have been shown to
downregulate the expression of BMPR2. As such, these
miRNAs can provide a mechanistic explanation for the ob-
served dysregulation of this protein in the development
of pulmonary vascular remodelling. Of note, the miRNA
cluster miR-17-92 has been found to be controlled by in-
flammatory cytokines, in particular by the acute-phase re-
actant interleukin-6 (IL-6) [58]. Elevated levels of IL-6
have been described in patients with idiopathic pulmonary
arterial hypertension [59, 60] and in patients with pulmon-
ary hypertension due to chronic obstructive pulmonary dis-
ease [61], chronic haemolysis in sickle cell disease [62] and
pulmonary hypertension due to liver cirrhosis [63]. Stimu-
lation of pulmonary arterial endothelial cells with IL-6 res-
ulted in activation of the transcription factor STAT3 (signal
transducer and activator of transcription) followed by sub-
sequent induction of miR-17-92 expression. This, in turn,
was shown to reduce levels of BMPR2. Of interest, consti-
tutional activation of STAT3 was found in distinct lesions
of the vessel wall of patients with pulmonary arterial hyper-
tension [64]. This ongoing activation of STAT3 might res-
ult in continuous induction of miRNAs and BMPR2 down-
regulation. Conversely, antagonism of these miRNAs by
oligonucleotides (“antagomiRs”) resulted in functional res-
toration of BMPR2 both in vitro and in vivo [65, 66]. In
animals carrying BMPR2 mutations, similar effects were
achieved by genetic transfection of functional BMPR2
[67]. These data emphasise the important role of a func-
tional STAT3-miRNA-BMPR2 pathway to prevent the de-
velopment of vascular remodelling within the pulmonary
circulation. Which specific components of the BMPR2
gene and its pathway will serve as therapeutic target in a
translational setting remains to be determined.
Inflammation is another emerging concept in the pathobio-
logy of vascular remodelling and includes the complex in-
teraction between humoral and cellular factors triggered by
infectious, toxic and autoimmune events. Cellular factors
include the accumulation of T and B lymphocytes, mono-
cytes and plasma cells within the vessel wall and surround-
ing tissue of patients with pulmonary hypertension [27,
68]. Moreover, many cytokines have been found to be dys-
regulated in the context of pulmonary hypertension, many
with unknown pathogenic relevance. However, levels of
several cytokines have been found to predict outcome of
the disease and, as prognostic markers, were more accurate
than haemodynamic parameters [60]. An elegant experi-
mental study has recently highlighted the important inter-
action between inflammation and BMPR2 status by show-
ing that defective BMPR2 signalling might induce the pro-
duction of inflammatory cytokines such as IL-6 and IL-8
in pulmonary arterial smooth muscle cells [69]. However,
it remains undetermined whether dysregulated BMPR2 or
increased levels of inflammatory cytokines are the initial
trigger of these events or, conversely, whether both factors
might augment one another within the vicious circle of pul-
monary vascular remodelling.
Conclusions
The pathogenesis of pulmonary hypertension is driven by
the triad of vasoconstriction, microthrombosis and remod-
elling of small pulmonary arteries. All of these factors, al-
though to a different extent, are present in most entities
that result in elevation of the pulmonary pressure. Vascular
remodelling is the most important and, to date, the least
treatable factor. As such, remodelling is the factor that still
defines pulmonary hypertension as a chronic and incurable
disease. Most of our understanding of pulmonary arterial
remodelling has been provided by insights into the regu-
lation and function of the growth factor receptor BMPR2.
Dysfunctional BMPR2 signalling is the major driving force
for a proproliferative and antiapoptotic state of vascular
cells. Targeted therapies with genetic vehicles and synthet-
ic oligonucleotides have shown promising results in exper-
imental and preclinical studies. Such therapies, however,
are still far from implementation in clinical practice.
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Figures (large format)
Figure 1
The three pieces in the pathogenesis of pulmonary hypertension. Pure vasoconstriction occurs in early disease; microthrombotic events
are observed at increasing frequency during evolution of the disease; remodelling of the small pulmonary arteries is arguably the most important
factor.
Figure 2
Features of pulmonary artery vascular remodelling in different cell types. All vascular cell types (endothelial cells, smooth muscle cells and
adventitial fibroblasts) are involved in pulmonary artery remodelling and are characterised by excessive proliferation. The accumulation of
myofibroblasts and extracellular matrix proteins within the endothelial layer is termed “neointima”. Plexiform lesions (shown by white star) are a
system of thin-walled, dilated vessels as consequence of endothelial proliferation. These lesions are found exclusively in pulmonary arterial
hypertension (PAH). The most prominent changes are observed within the vessel’s medial layer and mediated by a imbalance between
proproliferative and apoptotic activity of smooth muscle cells and transmigration of these cells and myofibroblasts in the endothelial layer. Within
the adventitial layer, neovascularisation of vasa vasorum and increased production of matrix proteins is observed (shown by Elastin-Van Gieson
(EVG) staining). These alterations result in excessive hyperplasia, increased vessel thickness and luminal occlusion (reviewed in [70]).
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Figure 3
Overview of important factors in pulmonary vascular remodelling. BMPR2 is expressed on pulmonary artery smooth muscle cells and is
the master regulator in remodelling of pulmonary arteries. Upon binding of ligands, BMPR2 and BMPR1 dimerise and activate proapoptotic
genes through the action of the transcription factors Smad and Id (inhibitor of differentiation). Dysregulation of this pathway, for example due to
mutations in BMPR2, results in a proproliferative state. Inflammatory cytokines (e.g. interleukin-6 [IL-6]) phosphorylate the transcription factor
STAT3 and induce the expression of miRNAs. MicroRNAs act as gene silencers and downregulate BMPR2, which directly inhibits cell cycle
regulators. Ion channels, serotonin transporters and receptors associated with tyrosine kinase signalling are also involved in mediating
vasoconstriction and remodelling.
Review article Swiss Med Wkly. 2015;145:w14202
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 8
